Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Regeneron Pharmaceuticals Inc ... in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 Revolutionizing ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

PARIS, March 21 (Reuters) - Healthcare companies Sanofi and Regeneron announced on Tuesday that their Dupixent product, which treats the skin disease atopic dermatitis, had won a new regulatory ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

Sanofi and Regeneron have announced that the US Food and Drug Administration (FDA) has approved a label update for Dupixent (dupilumab) in atopic dermatitis. The US label for the IL-4 and IL-13 ...

Dupixent is an IL-4 receptor alpha antagonist that has been approved for the treatment of adults with moderate-to-severe atopic dermatitis, as well as asthma, chronic rhinosinusitis with nasal ...

Dupilumab is approved for atopic dermatitis in children aged 6 months ... Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and ...